FDA rejects Zarnestra -- for now

As expected, the FDA has formally rejected Johnson & Johnson's Zarnestra for acute myeloid leukemia. Given the FDA advisory council's decision last month that one Phase II trial provided insufficient evidence to back the application, that ruling had been factored in by most analysts. J&J was looking for an FDA approval to use the drug on seniors who were not good candidates for chemotherapy. J&J said it isn't discouraged by the rejection, though. The company says it is "committed" to Zarnestra and is studying the FDA's response to determine what its next step will be.

- read this story from TheStreet.com for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.